Literature DB >> 27465474

Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.

Keisuke Arai1, Takumi Fukumoto2, Masahiro Kido2, Motofumi Tanaka2, Kaori Kuramitsu2, Hisoka Kinoshita2, Shohei Komatsu2, Daisuke Tsugawa2, Sachio Terai2, Taku Matsumoto2, Tadahiro Goto2, Sadaki Asari2, Hirochika Toyama2, Tetsuo Ajiki2, Yonson Ku2.   

Abstract

PURPOSE: We assessed the predictive value of the preoperative neutrophil-to-lymphocyte ratio (NLR) in patients who underwent a two-stage treatment combining reductive surgery and percutaneous isolated hepatic perfusion for multiple hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
METHODS: Forty-two patients underwent the two-stage treatment between January 2000 and December 2014 at Kobe University Hospital (Hyogo, Japan). The NLR was calculated from lymphocyte and neutrophil counts in the preoperative routine blood test. Clinical data and overall survival were compared statistically and multivariate analysis was done to identify prognostic factors.
RESULTS: The median survival of patients with a preoperative NLR > 2.3 was 14.9 months (n = 13), whereas that of patients with a preoperative NLR ≤ 2.3 was 26.1 months (n = 29; P = 0.022). A preoperative NLR > 2.3 was an independent prognostic factor in patients with multiple HCC with PVTT [hazard ratio (HR) 2.329; 95 % confidence interval (CI) 1.058-5.667; P = 0.036].
CONCLUSION: Based on the results of this study, an elevated preoperative NLR is an independent predictive risk factor for patients undergoing two-stage treatment for multiple HCC with PVTT.

Entities:  

Keywords:  Hepatocellular carcinoma; Invasion to the portal vein; Neutrophil-to-lymphocyte ratio

Mesh:

Year:  2016        PMID: 27465474     DOI: 10.1007/s00595-016-1384-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  30 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Comparisons of financial and short-term outcomes between laparoscopic and open hepatectomy: benefits for patients and hospitals.

Authors:  Yoshikuni Kawaguchi; Yuichiro Otsuka; Hironori Kaneko; Motoki Nagai; Yukihiro Nomura; Mariko Yamamoto; Masahide Otani; Yuichi Ohashi; Kotaro Sugawara; Daisuke Koike; Takashi Ishida; Norihiro Kokudo; Nobutaka Tanaka
Journal:  Surg Today       Date:  2015-05-30       Impact factor: 2.549

5.  Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.

Authors:  Norifumi Harimoto; Ken Shirabe; Hidekazu Nakagawara; Takeo Toshima; Yo-Ichi Yamashita; Toru Ikegami; Tomoharu Yoshizumi; Yuji Soejima; Tetsuo Ikeda; Yoshihiko Maehara
Journal:  Transplantation       Date:  2013-12-15       Impact factor: 4.939

6.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Authors:  Sadaki Asari; Ippei Matsumoto; Hirochika Toyama; Makoto Shinzeki; Tadahiro Goto; Jun Ishida; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2015-06-25       Impact factor: 2.549

7.  Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.

Authors:  E Villa; A Moles; I Ferretti; P Buttafoco; A Grottola; M Del Buono; M De Santis; F Manenti
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection.

Authors:  Weijia Liao; Jingmei Zhang; Qun Zhu; Liling Qin; Wenmin Yao; Biao Lei; Wuxiang Shi; Shengguang Yuan; Syed Abdul Tahir; Junfei Jin; Songqing He
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

View more
  7 in total

1.  The accumulation of regulatory T cells in the hepatic hilar lymph nodes in biliary atresia.

Authors:  Naoya Sakamoto; Toshihiro Muraji; Haruo Ohtani; Kouji Masumoto
Journal:  Surg Today       Date:  2017-03-14       Impact factor: 2.549

Review 2.  Understanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases.

Authors:  Xu Wang; Lin Qiu; Ziyi Li; Xiang-Yang Wang; Huanfa Yi
Journal:  Front Immunol       Date:  2018-11-09       Impact factor: 7.561

Review 3.  Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma.

Authors:  Mariam Mroweh; Thomas Decaens; Patrice N Marche; Zuzana Macek Jilkova; Flora Clément
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

4.  Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Authors:  A Rebonato; L Graziosi; D Maiettini; E Marino; V De Angelis; L Brunese; S Mosca; G Metro; M Rossi; G Orgera; M Scialpi; A Donini
Journal:  Gastroenterol Res Pract       Date:  2017-08-15       Impact factor: 2.260

5.  Human leukocyte antigen gene polymorphisms are associated with systemic inflammation in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xiao-Long Wu; Zhi-Yu Li; Xin-Yu Bi; Hong Zhao; Jian-Jun Zhao; Jian-Guo Zhou; Yue Han; Zhen Huang; Ye-Fan Zhang; Jian-Qiang Cai
Journal:  Cancer Manag Res       Date:  2018-07-31       Impact factor: 3.989

6.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

7.  A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.

Authors:  Juanfang Liu; Wenguang Zhang; Rongfang Niu; Yahua Li; Xueliang Zhou; Xinwei Han
Journal:  Saudi Med J       Date:  2020-04       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.